An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus

被引:36
作者
Feil, Susanne C. [1 ]
Hamilton, Stephanie
Krippner, Guy Y.
Lin, Bo
Luttick, Angela
McConnell, Darryl B.
Nearn, Roland
Parker, Michael W. [1 ,2 ]
Ryan, Jane
Stanislawski, Pauline C.
Tucker, Simon P.
Watson, Keith G.
Morton, Craig J. [1 ]
机构
[1] St Vincents Inst, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia
[2] Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst Bio21, Parkville, Vic 3010, Australia
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2012年 / 3卷 / 04期
关键词
antiviral; rhinovirus; capsid; inhibitor; VITRO ANTIVIRAL ACTIVITY; HEALTHY-VOLUNTEERS; DOUBLE-BLIND; 3C PROTEASE; PIRODAVIR; COLDS; PLECONARIL; SAFETY; PHARMACOKINETICS; RUPRINTRIVIR;
D O I
10.1021/ml2002955
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Respiratory infections caused by human rhinovirus are responsible for severe exacerbations of underlying clinical conditions such as asthma in addition to their economic cost in terms of lost working days due to illness. While several antiviral compounds for treating rhinoviral infections have been discovered, none have succeeded, to date, in reaching approval for clinical use. We have developed a potent, orally available rhinovirus inhibitor 6 that has progressed through early clinical trials. The compound shows favorable pharmacokinetic and activity profiles and has a confirmed mechanism of action through crystallographic studies of a rhinovirus compound complex. The compound has now progressed to phase IIb clinical studies of its effect on natural rhinovirus infection in humans.
引用
收藏
页码:303 / 307
页数:5
相关论文
共 25 条
[11]   Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: Results of 2 double-blind, randomized, placebo-controlled trials [J].
Hayden, FG ;
Herrington, DT ;
Coats, TL ;
Kim, K ;
Cooper, EC ;
Villano, SA ;
Liu, SY ;
Hudson, S ;
Pevear, DC ;
Collett, M ;
McKinlay, M .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (12) :1523-1532
[12]   INTRANASAL PIRODAVIR (R77,975) TREATMENT OF RHINOVIRUS COLDS [J].
HAYDEN, FG ;
HIPSKIND, GJ ;
WOERNER, DH ;
EISEN, GF ;
JANSSENS, M ;
JANSSEN, PAJ ;
ANDRIES, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :290-294
[13]   SAFETY AND EFFICACY OF INTRANASAL PIRODAVIR (R77975) IN EXPERIMENTAL RHINOVIRUS INFECTION [J].
HAYDEN, FG ;
ANDRIES, K ;
JANSSEN, PAJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (04) :727-732
[14]   Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers [J].
Hsyu, PH ;
Pithavala, YK ;
Gersten, M ;
Penning, CA ;
Kerr, BM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :392-397
[15]   In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease [J].
Patick, AK ;
Brothers, MA ;
Maldonado, F ;
Binford, S ;
Maldonado, O ;
Fuhrman, S ;
Petersen, A ;
Smith, GJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2267-2275
[16]   In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease [J].
Patick, AK ;
Binford, SL ;
Brothers, MA ;
Jackson, RL ;
Ford, CE ;
Diem, MD ;
Maldonado, F ;
Dragovich, PS ;
Zhou, R ;
Prins, TJ ;
Fuhrman, SA ;
Meador, JW ;
Zalman, LS ;
Matthews, DA ;
Worland, ST .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) :2444-2450
[17]   Rhinovirus chemotherapy [J].
Patick, Amy K. .
ANTIVIRAL RESEARCH, 2006, 71 (2-3) :391-396
[18]   Activity of pleconaril against enteroviruses [J].
Pevear, DC ;
Tull, TM ;
Seipel, ME ;
Groarke, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2109-2115
[19]   Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses [J].
Pevear, DC ;
Hayden, FG ;
Demenczuk, TM ;
Barone, LR ;
McKinlay, MA ;
Collettt, MS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4492-4499